Trial Profile
Study B2C111045, A Dose-Finding Study of GW642444 Versus Placebo in Patients With COPD.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2016
Price :
$35
*
At a glance
- Drugs Vilanterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- 12 Jan 2012 Results published in Chest.
- 22 Sep 2010 Safety results were presented at the 20th Annual Congress of the European Respiratory Society.
- 22 Sep 2010 Results presented at the European Respiratory Society congress, according to a GSK media release.